NMD Pharma has secured clearance for an Investigational New Drug (IND) application from the US Food and Drug Administration to commence a Phase IIb clinical trial of muscle-targeted therapy, NMD670, for generalised myasthenia gravis (gMG).
This study will have gMG patients who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The dose range-finding, double-blind, placebo-controlled trial will assess the twice-a-day dose of NMD670 in gMG patients.
To be conducted at both US and European study centres, the trial will commence subject enrolment soon.
A muscle-targeted small molecule inhibitor specifically targeting the ClC-1 chloride ion channel in skeletal muscles, NMD670 is being developed to alleviate persistent or fluctuating symptoms in gMG patients who are not fully responsive to existing standard treatments.
Recent Phase I/IIa trial results have shown promising clinical proof-of-mechanism for ClC-1 inhibitors in gMG patients, along with a strong safety and tolerability profile for NMD670.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNMD Pharma announced in November last year that it secured approximately $80m in a Series B financing round.
These funds are earmarked to complete three Phase II studies of NMD670, including trials for gMG, spinal muscular atrophy, and Charcot-Marie-Tooth disease.
NMD Pharma CEO Thomas Holm Pedersen said: “This is an important milestone for NMD Pharma, enabling us to progress our lead development candidate NMD670 into a Phase IIb trial in the US in generalised myasthenia gravis patients with AChR and MuSK positive antibodies.
“It follows positive Phase I/IIa data which provided proof-of-mechanism and where clinically and statistically significant effects were seen in patients.
“We are excited to bring forward a unique and validated muscle-targeted approach with promise to provide improvements in muscle function leading to clinically meaningful improvements in activities of daily living and quality of life.”
